AKT1 and breast cancer: Given these insights, our research interest pivots on exploring whether the concomitant administration of PEDF with chemotherapeutic agents like Dox could yield synergistic effects, not only in inhibiting tumour growth but also in modulating critical pathways such as MAPK and PI3K/AKT signalling pathways and metastasis in BC.